Related Experiment Video

Updated: Jun 23, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer

Shinsuke Homma1, Yukio Ishii, Yuko Morishima

  • 1Department of Respiratory Medicine, University of Tsukuba, Tsukuba, Japan.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|May 7, 2009
PubMed
Abstract

Insights

The Nrf2 system drives cancer cell proliferation and drug resistance. Inhibiting Nrf2 (NF-E2-related factor 2) with small interfering RNA (siRNA) reduced cancer cell growth and increased sensitivity to cisplatin, highlighting Nrf2 as a therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • NF-E2-related factor 2 (Nrf2) is a transcription factor crucial for antioxidant and detoxification pathways.
  • Nrf2 is frequently upregulated in various cancer cells, suggesting a role in tumorigenesis and treatment resistance.

Purpose of the Study:

  • To investigate the role of Nrf2 in cancer cell proliferation.
  • To determine the impact of Nrf2 on resistance to anticancer drugs, specifically cisplatin.

Main Methods:

  • Utilized three human lung cancer cell lines (A549, NCI-H292, LC-AI) with varying Nrf2 activation levels.
  • Employed Nrf2-specific small interfering RNA (Nrf2-siRNA) to knock down Nrf2 expression.
  • Assessed cell proliferation, cisplatin resistance, gene expression (antioxidant, detoxification, drug efflux pumps), glutathione levels, DNA crosslinking, apoptosis, and cell cycle progression.

Main Results:

  • A549 cells, with high Nrf2 activation, exhibited greater resistance to cisplatin compared to NCI-H292 and LC-AI cells.
  • Nrf2 knockdown significantly sensitized A549 cells to cisplatin and inhibited proliferation.
  • Nrf2-siRNA reduced self-defense gene expression and glutathione levels, increased DNA crosslinking and apoptosis, and arrested the cell cycle at G1 phase in A549 and NCI-H292 cells.

Conclusions:

  • The Nrf2 system is vital for promoting cancer cell proliferation and conferring resistance to chemotherapy.
  • Targeting Nrf2 presents a promising strategy to enhance the efficacy of anticancer therapies.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...